Dynavax Technologies Corporation (DVAX): Price and Financial Metrics


Dynavax Technologies Corporation (DVAX): $11.38

-0.03 (-0.26%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add DVAX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

DVAX POWR Grades

  • DVAX scores best on the Value dimension, with a Value rank ahead of 96.66% of US stocks.
  • DVAX's strongest trending metric is Growth; it's been moving down over the last 177 days.
  • DVAX's current lowest rank is in the Stability metric (where it is better than 2.55% of US stocks).

DVAX Stock Summary

  • With a price/earnings ratio of 4.69, DYNAVAX TECHNOLOGIES CORP P/E ratio is greater than that of about only 9.1% of stocks in our set with positive earnings.
  • Over the past twelve months, DVAX has reported earnings growth of -1,476.91%, putting it ahead of only 0.97% of US stocks in our set.
  • Revenue growth over the past 12 months for DYNAVAX TECHNOLOGIES CORP comes in at 177.83%, a number that bests 95.29% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to DYNAVAX TECHNOLOGIES CORP, a group of peers worth examining would be DOCS, IRWD, NICE, UAVS, and SWAV.
  • DVAX's SEC filings can be seen here. And to visit DYNAVAX TECHNOLOGIES CORP's official web site, go to www.dynavax.com.

DVAX Valuation Summary

  • In comparison to the median Healthcare stock, DVAX's price/sales ratio is 60.78% lower, now standing at 2.
  • DVAX's price/earnings ratio has moved up 16.9 over the prior 230 months.

Below are key valuation metrics over time for DVAX.

Stock Date P/S P/B P/E EV/EBIT
DVAX 2023-01-20 2.0 2.9 4.5 4.5
DVAX 2023-01-19 1.9 2.8 4.4 4.4
DVAX 2023-01-18 1.9 2.8 4.4 4.4
DVAX 2023-01-17 2.0 2.9 4.5 4.5
DVAX 2023-01-13 2.0 2.9 4.5 4.5
DVAX 2023-01-12 2.0 2.9 4.5 4.5

DVAX Growth Metrics

    The 4 year net cashflow from operations growth rate now stands at -2.9%.
  • Its year over year revenue growth rate is now at 295.15%.
  • Its 4 year cash and equivalents growth rate is now at 72.63%.
DVAX's revenue has moved up $723,012,000 over the prior 67 months.

The table below shows DVAX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 733.261 148.265 320.633
2022-06-30 673.796 152.916 228.394
2022-03-31 470.099 247.053 104.112
2021-12-31 439.442 335.528 72.144
2021-09-30 263.922 199.288 -38.533
2021-06-30 169.066 105.256 -5.702

DVAX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • DVAX has a Quality Grade of B, ranking ahead of 88.86% of graded US stocks.
  • DVAX's asset turnover comes in at 0.367 -- ranking 129th of 681 Pharmaceutical Products stocks.
  • LJPC, ABT, and CVM are the stocks whose asset turnover ratios are most correlated with DVAX.

The table below shows DVAX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.367 0.719 0.023
2021-03-31 0.312 0.715 -0.092
2020-12-31 0.144 0.701 -0.128
2020-09-30 0.123 0.612 -0.182
2020-06-30 0.119 0.519 -0.278
2020-03-31 0.146 0.505 -0.263

DVAX Price Target

For more insight on analysts targets of DVAX, see our DVAX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $20.50 Average Broker Recommendation 1.38 (Strong Buy)

DVAX Stock Price Chart Interactive Chart >

Price chart for DVAX

DVAX Price/Volume Stats

Current price $11.38 52-week high $17.48
Prev. close $11.41 52-week low $7.26
Day low $11.23 Volume 1,198,092
Day high $11.56 Avg. volume 1,338,340
50-day MA $11.48 Dividend yield N/A
200-day MA $11.75 Market Cap 1.45B

Dynavax Technologies Corporation (DVAX) Company Bio


Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company, using TLR biology to discover and develop novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. The company was founded in 1996 and is based in Berkeley, California.


DVAX Latest News Stream


Event/Time News Detail
Loading, please wait...

DVAX Latest Social Stream


Loading social stream, please wait...

View Full DVAX Social Stream

Latest DVAX News From Around the Web

Below are the latest news stories about DYNAVAX TECHNOLOGIES CORP that investors may wish to consider to help them evaluate DVAX as an investment opportunity.

Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023

-- China commercial launch in multiple provinces and municipalities expected to begin in Q1 2023, and Clover anticipates a significant and sustained long-term annual booster market for its premium, broadly protective protein-based COVID-19 vaccines in China -- -- SCB-2019 (CpG 1018/Alum) anticipated to receive emergency use authorization (EUA) in at least one additional country and to complete multiple EUA submissions during H1 2023, with commercial value driven via bilateral supply agreements e

Yahoo | January 16, 2023

The 7 Most Undervalued Long-Term Stocks to Buy in January

The undervalued long-term stocks mentioned are a combination of winners and losers from 2022.

Will Ashworth on InvestorPlace | January 14, 2023

Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Highlights and Phase 1 Shingles Topline Results

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative vaccines, today announced preliminary, unaudited financial highlights for the fourth quarter and full year ending December 31, 2022 and Phase 1 shingles topline results.

Yahoo | January 9, 2023

7 Cheap Stocks That Wall Street Analysts Still Love

The number of cheap stocks Wall Street analysts love might have gone down over the past year, but there are still plenty of options.

Will Ashworth on InvestorPlace | January 6, 2023

Dynavax Technologies Corporation (DVAX) can beat the pack with these strategies

A share of Dynavax Technologies Corporation (NASDAQ:DVAX) closed at $11.42 per share on Thursday, up from $11.41 day before. While Dynavax Technologies Corporation has overperformed by 0.09%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, DVAX fell by -18.66%, with highs and lows ranging from $17.48 […]

US Post News | December 23, 2022

Read More 'DVAX' Stories Here

DVAX Price Returns

1-mo 6.95%
3-mo 0.98%
6-mo -20.64%
1-year -12.26%
3-year 125.35%
5-year -30.82%
YTD 6.95%
2022 -24.38%
2021 216.18%
2020 -22.20%
2019 -37.49%
2018 -51.07%

Continue Researching DVAX

Want to see what other sources are saying about Dynavax Technologies Corp's financials and stock price? Try the links below:

Dynavax Technologies Corp (DVAX) Stock Price | Nasdaq
Dynavax Technologies Corp (DVAX) Stock Quote, History and News - Yahoo Finance
Dynavax Technologies Corp (DVAX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7566 seconds.